Pan Li Email & Phone Number

Shanghai, China

Building up and leading an early drug discovery team, including medicinal chemists, analytical chemists, biologists, DMPK and CADD for the discovery of novel small molecules as antiviral and anticancer agents.Targeting MDSC for immunooncology;Targeting STING for oncology/autoimmune diseases;PROTAC/Molecular Glue (MG) for protein degradation

Shanghai

Responsible for new targets investigation, new projects proposal, approval and budget planning; Projects leading from hits to leads (H2L), lead optimization (LO), PCC identification/selection to IND filing.

Leading teams of the following projects from hit to pre-clinical candidates:- Discovery of non-CDN small molecule agonist of STING for cancer immunotherapy;- Discovery of first-in-class small molecule inhibitors of PD-1/PD-L1 immune checkpoint;- Discovery of best-in-class small molecule inhibitors of IDO.

Boston, MA

• Phenotypic approach to anti-cancer agents: from a single hit through to late stage lead optimization resulting in 3 molecules under consideration as pre-clinical candidates
• Utilized structure based drug design strategy to discover novel c-Met inhibitors as anti-cancer agents from lead generation through lead optimization; key contributor of VX-140 and VX-198 as pre-clinical candidates
• Co-inventor and contributor for the discovery of new DNA-PK clinical drug candidate VX-984 using SBDD
• Designed and synthesized small molecule library targeting protein kinase GSK3β, key contributor of VX-608 as pre-clinical candidates
• Worked with antiviral team to improve physiochemical properties of VX-222, led to the discovery of a novel lactam-containing non-nucleoside class of HCV NS5B inhibitors VX-456 and VX-929 as pre-clinical drug candidates

Medford, MA

• Responsible for setting up a new chemistry lab for a start-up company; Designed and synthesized mixture peptide libraries and small molecules targeting protein kinases; Skilled in using Gilson HPLC system and Chrybdis.
• Designed and synthesized mixture peptide libraries targeting protein kinase inhibitor discovery
• Developed solution and solid phase methods for synthesis of aminoflavone combinatorial libraries for the protein kinase inhibitor SAR studies
• Developed novel chemistry for the synthesis of fluorine-containing amino acids.

Cambridge, Massachusetts

Ba, Polymer Chemistry

Ph.D. (Advisor: Kang Zhao), Organic Chemistry